Incidence of NRAS, KRAS, and NF1 mutations in hematologic malignancies
| . | NRAS . | KRAS . | NF1 . |
|---|---|---|---|
| JMML | 17% (9-30) | 8% (3-18) | 7% (4-15) |
| CMML | 19% (2-43) | 11% (6-15) | ND |
| AML | 11% (10-44) | 5% (1-13) | ∼ 5% (0-7) |
| MDS | 5% (4-9) | ∼ 1% | ∼ 3% (0-9) |
| ALL | 10% (0-18) | 4% (0-5) | 6% (3-8)* |
| MM | 18% (17-30) | 8% (6-9) | ND |
| . | NRAS . | KRAS . | NF1 . |
|---|---|---|---|
| JMML | 17% (9-30) | 8% (3-18) | 7% (4-15) |
| CMML | 19% (2-43) | 11% (6-15) | ND |
| AML | 11% (10-44) | 5% (1-13) | ∼ 5% (0-7) |
| MDS | 5% (4-9) | ∼ 1% | ∼ 3% (0-9) |
| ALL | 10% (0-18) | 4% (0-5) | 6% (3-8)* |
| MM | 18% (17-30) | 8% (6-9) | ND |
These data are tabulated from published series that used the current definition for each disease, distinguished clearly between NRAS and KRAS mutations and, with 1 exception (*T-ALL only), did not restrict inclusion based on an underlying genetic alteration or specific subtype of disease. The supplemental Materials (available on the Blood Web site; see the Supplemental Materials link at the top of the online article) include tables and references listing the primary sources for the data shown here by disease category, along with the number of cases sequenced in each report.
ND indicates not determined.